Cargando…
Will We Unlock the Benefit of Metformin for Patients with Lung Cancer? Lessons from Current Evidence and New Hypotheses
Metformin has been under basic and clinical study as an oncological repurposing pharmacological agent for several years, stemming from observational studies which consistently evidenced that subjects who were treated with metformin had a reduced risk for development of cancer throughout their lives,...
Autores principales: | Barrios-Bernal, Pedro, Zatarain-Barrón, Zyanya Lucia, Hernández-Pedro, Norma, Orozco-Morales, Mario, Olivera-Ramírez, Alejandra, Ávila-Moreno, Federico, Colín-González, Ana Laura, Cardona, Andrés F., Rosell, Rafael, Arrieta, Oscar |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9318003/ https://www.ncbi.nlm.nih.gov/pubmed/35890085 http://dx.doi.org/10.3390/ph15070786 |
Ejemplares similares
-
Metformin Enhances TKI-Afatinib Cytotoxic Effect, Causing Downregulation of Glycolysis, Epithelial–Mesenchymal Transition, and EGFR-Signaling Pathway Activation in Lung Cancer Cells
por: Barrios-Bernal, Pedro, et al.
Publicado: (2022) -
Obesity paradox and lung cancer, metformin-based therapeutic opportunity?
por: Barrios-Bernal, Pedro, et al.
Publicado: (2023) -
Comprehensive review of fetal adenocarcinoma of the lung
por: Ricaurte, Luisa María, et al.
Publicado: (2018) -
Chronic and Severe Non-Lichenoid Oral Ulcers Induced by Nivolumab − Diagnostic and Therapeutic Challenge: A Case Report
por: Cardona, Andrés F., et al.
Publicado: (2020) -
Interplay between Cellular and Molecular Inflammatory Mediators in Lung Cancer
por: Orozco-Morales, Mario, et al.
Publicado: (2016)